Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The Role of Regulator of G-Protein Signaling 5 During Atherosclerosis Progression

EF 2013-14

Résumé
Atherosclerosis, the underlying cause of events such as heart attacks and strokes, is a chronic vascular disease that remains the leading cause of death in both developed and developing countries. This disease is characterized by the development of plaque within arterial vessels that lead to various cardiovascular complications. With the current rise in atherosclerosis risk factors such as obesity and an aging population, future health care teams will face severe challenges in treating this epidemic, with an accompanying increased burden on healthcare spending. Despite extensive scientific research, the complex mechanism by which atherosclerosis initiates and progresses remains poorly understood. Concomitantly, the treatment of this disease remains inadequate with several limitations. Statins, a group of cholesterol-lowering drugs, continue to be the most widely used treatment for atherosclerosis patients. Elucidating the underlying mechanisms of this disease will lead to better understanding of the pathology, its complications, and treatment options. The progression of atherosclerosis depends on the activation and repression of numerous elaborate signaling pathways in cells within the blood vessel wall, as well as different types of inflammatory cells. A protein known as Regulator of G-protein Signaling subtype 5 (RGS5) is a potent inhibitor of specific signaling pathways known as G-protein signaling that have been shown to induce various processes of atherosclerosis. Therefore, our lab hypothesized that RGS5, by inhibiting these atherogenic pathways, would inhibit the development of plaques within arterial vessels. Consistent with our hypothesis, previous experiments by our lab has demonstrated that disruption of the functional RGS5 protein leads to lower survivorship in mice, as well as larger atherosclerotic plaque size in the arterial wall. Moreover, recent preliminary results suggest that treating isolated cells from the vessel wall with fluvastatin, a commonly prescribed statin, causes a large increase in the level of RGS5, consistent with a protective effect of this protein towards atherosclerosis progression. My project will now focus on demonstrating the specific cellular effects of RGS5 that lead to the inhibition of atherosclerotic plaque development and the importance of this mechanism in mediating the therapeutic effects of statin treatment. I will be isolating cells from arterial vessels, and investigating the role of RGS5 in the cellular response to different signaling molecules. Subsequently, the effect of the statin-induced increase in RGS5 levels will be assessed for different cellular responses. Finally, these experiments will be complemented by animal investigations in which the beneficial effects of statin treatment will be assessed in genetically modified mice with a lack of functional RGS5 protein. We hypothesize that these mice will have decreased therapeutic effects from statin treatment as compared to mice with normal RGS5 function. Understanding the role of RGS5 in inhibiting the progression of atherosclerosis, and its potentially crucial function in mediating the therapeutic effects of statin treatment, will allow us to target this molecular pathway and provide more effective treatment that will go beyond the cholesterol-reducing effects of statins.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311985
Name
Sattar Joobin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Regulator of G-Protein Signaling 5 During Atherosclerosis Progression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atherosclerosis; Cell Recruitment; G-Protein Coupled Receptor Signaling; Gene Expression; Regulator Of G-Protein Signaling; Statin; Vascular Smooth Muscle Cell
Abstract
Atherosclerosis, the underlying cause of events such as heart attacks and strokes, is a chronic vascular disease that remains the leading cause of death in both developed and developing countries. This disease is characterized by the development of plaque within arterial vessels that lead to various cardiovascular complications. With the current rise in atherosclerosis risk factors such as obesity and an aging population, future health care teams will face severe challenges in treating this epidemic, with an accompanying increased burden on healthcare spending. Despite extensive scientific research, the complex mechanism by which atherosclerosis initiates and progresses remains poorly understood. Concomitantly, the treatment of this disease remains inadequate with several limitations. Statins, a group of cholesterol-lowering drugs, continue to be the most widely used treatment for atherosclerosis patients. Elucidating the underlying mechanisms of this disease will lead to better understanding of the pathology, its complications, and treatment options. The progression of atherosclerosis depends on the activation and repression of numerous elaborate signaling pathways in cells within the blood vessel wall, as well as different types of inflammatory cells. A protein known as Regulator of G-protein Signaling subtype 5 (RGS5) is a potent inhibitor of specific signaling pathways known as G-protein signaling that have been shown to induce various processes of atherosclerosis. Therefore, our lab hypothesized that RGS5, by inhibiting these atherogenic pathways, would inhibit the development of plaques within arterial vessels. Consistent with our hypothesis, previous experiments by our lab has demonstrated that disruption of the functional RGS5 protein leads to lower survivorship in mice, as well as larger atherosclerotic plaque size in the arterial wall. Moreover, recent preliminary results suggest that treating isolated cells from the vessel wall with fluvastatin, a commonly prescribed statin, causes a large increase in the level of RGS5, consistent with a protective effect of this protein towards atherosclerosis progression. My project will now focus on demonstrating the specific cellular effects of RGS5 that lead to the inhibition of atherosclerotic plaque development and the importance of this mechanism in mediating the therapeutic effects of statin treatment. I will be isolating cells from arterial vessels, and investigating the role of RGS5 in the cellular response to different signaling molecules. Subsequently, the effect of the statin-induced increase in RGS5 levels will be assessed for different cellular responses. Finally, these experiments will be complemented by animal investigations in which the beneficial effects of statin treatment will be assessed in genetically modified mice with a lack of functional RGS5 protein. We hypothesize that these mice will have decreased therapeutic effects from statin treatment as compared to mice with normal RGS5 function. Understanding the role of RGS5 in inhibiting the progression of atherosclerosis, and its potentially crucial function in mediating the therapeutic effects of statin treatment, will allow us to target this molecular pathway and provide more effective treatment that will go beyond the cholesterol-reducing effects of statins.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sattar, Joobin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~